Darzalex

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Flag link:
Danish biotech Genmab hit by ending of trial using key cancer drug
Danish biotech Genmab hit by ending of trial using key cancer drug
Reuters
Genmab
JNJ
Janssen
Darzalex
Flag link:
Janssen obtains FDA approval for Darzalex (multiple myeloma)
Janssen obtains FDA approval for Darzalex (multiple myeloma)
GoinPharma
Janssen
JNJ
Darzalex
Takeda
Velcade
Multiple Myeloma
FDA
Flag link:
3 Drugs That Are Moving the Needle at Johnson & Johnson
3 Drugs That Are Moving the Needle at Johnson & Johnson
Motley Fool
JNJ
Darzalex
Zytiga
Stelara
earnings
Flag link:
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Motley Fool
JNJ
Stelara
Zytiga
Darzalex
oncology
immunology
Flag link:
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half
Fierce Pharma
ASH17
JNJ
Darzalex
Multiple Myeloma
Janssen
Flag link:
Genmab and J&J 'love' partnership as some ponder takeover
Genmab and J&J 'love' partnership as some ponder takeover
Yahoo/Reuters
Genmab
JNJ
M&A
Darzalex
Flag link:
J&J multiple myeloma drug succeeds in first-line combination study
J&J multiple myeloma drug succeeds in first-line combination study
Yahoo/Reuters
JNJ
Multiple Myeloma
clinical trials
Darzalex
Flag link:
5 Key Drugs Critical to Johnson & Johnson's Future
5 Key Drugs Critical to Johnson & Johnson's Future
Motley Fool
JNJ
Stelara
Xarelto
Imbruvia
Zytiga
Darzalex
Flag link:
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Motley Fool
JNJ
Remicade
Stelara
drug pricing
Imbruvica
Xarelto
Darzalex
devices
consumer health
Flag link:
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Endpoints
Genmab
daratumumab
Darzalex
Multiple Myeloma
clinical trials
Flag link:
Johnson & Johnson nabs another combo approval for myeloma star Darzalex
Johnson & Johnson nabs another combo approval for myeloma star Darzalex
Fierce Pharma
JNJ
Multiple Myeloma
Darzalex
Flag link:
3 Big Pharma Companies With the Best Pipelines
3 Big Pharma Companies With the Best Pipelines
Motley Fool
JNJ
Actelion
Darzalex
Novartis
Cosentyx
Jakavi
Lucentis
Tasigna
Roche
Venclexta
Tecentriq
emicizumab
Flag link:
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma
Fierce Pharma
Darzalex
JNJ
Genmab
non-Hodgkin's lymphoma
Flag link:
J&J pulls the plug on PhII study for NHL after Darzalex falls short
J&J pulls the plug on PhII study for NHL after Darzalex falls short
Endpoints
JNJ
clinical trials
Darzalex
Flag link:
4 Reasons Johnson & Johnson Surged 8% in February
4 Reasons Johnson & Johnson Surged 8% in February
Motley Fool
JNJ
Darzalex
Actelion
Donald Trump
Flag link:
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Motley Fool
JNJ
Remicade
Darzalex
Genmab
Multiple Myeloma
Flag link:
Is This Johnson & Johnson's Next Billion-Dollar Blockbuster?
Is This Johnson & Johnson's Next Billion-Dollar Blockbuster?
Motley Fool
JNJ
Darzalex
Multiple Myeloma
Flag link:
3 Biggest Risks for Celgene Corporation
3 Biggest Risks for Celgene Corporation
Motley Fool
Celgene
Darzalex
Multiple Myeloma
Allergan
generics
Abraxane
Revlimid
Flag link:
You'll Never Guess Who Owns the Most Spectacular New Cancer Drug
You'll Never Guess Who Owns the Most Spectacular New Cancer Drug
Motley Fool
JNJ
Darzalex
Multiple Myeloma
Flag link:

Pages